Breast Cancer – Pipeline Review, H1 2012

Introduction

Global Markets Direct’s, 'Breast Cancer - Pipeline Review, H1 2012', provides an overview of the Breast Cancer therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. 'Breast Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Breast Cancer.
- A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Breast Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Breast Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Breast Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
[Studien Infos ausblenden]

Table of Contents
Table of Contents 2
List of Tables 13
List of Figures 23
Introduction 24
Global Markets Direct Report Coverage 24
Breast Cancer Overview 25
Therapeutics Development 26
An Overview of Pipeline Products for Breast Cancer 26
Breast Cancer Therapeutics under Development by Companies 28
Breast Cancer Therapeutics under Investigation by Universities/Institutes 45
Late Stage Products 72
Comparative Analysis 72
Mid Clinical Stage Products 73
Comparative Analysis 73
Early Clinical Stage Products 74
Comparative Analysis 74
Discovery and Pre-Clinical Stage Products 75
Comparative Analysis 75
Breast Cancer Therapeutics – Products under Development by Companies 76
Breast Cancer Therapeutics – Products under Investigation by Universities/Institutes 106
Companies Involved in Breast Cancer Therapeutics Development 199
Bristol-Myers Squibb Company 199
Boehringer Ingelheim GmbH 200
F. Hoffmann-La Roche Ltd. 201
Kyowa Hakko Kirin Co., Ltd. 203
Celsion Corporation 204
Abbott Laboratories 205
Biogen Idec Inc. 206
Amgen Inc. 207
Sanofi-Aventis 208
Adherex Technologies Inc. 209
AstraZeneca PLC 210
Eli Lilly and Company 211
Viralytics Ltd. 212
GlaxoSmithKline plc 213
Seattle Genetics, Inc. 214
Tekmira Pharmaceuticals Corp. 215
Genentech, Inc. 216
Nektar Therapeutics 217
Biotec Pharmacon ASA 218
Bavarian Nordic A/S 219
Daiichi Sankyo Company, Ltd 220
Immunovative Therapies, Ltd. 401
Oncozyme Pharma Inc. 402
BerGenBio AS 403
CytomX, LLC. 404
Breast Cancer – Therapeutics Assessment 405
Assessment by Monotherapy Products 405
Assessment by Combination Products 406
Assessment by Route of Administration 407
Assessment by Molecule Type 410
Drug Profiles 413
Halaven - Drug Profile 413
SNDX 275 - Drug Profile 414
Nexavar - Drug Profile 416
RG3502 - Drug Profile 418
Pertuzumab - Drug Profile 419
Decapeptyl - Drug Profile 420
NKTR-102 - Drug Profile 421
Tavocept - Drug Profile 423
Avastin - Drug Profile 425
Faslodex - Drug Profile 427
Afinitor - Drug Profile 428
BSI-201 - Drug Profile 430
IMC-1121B - Drug Profile 432
NeuVax - Drug Profile 434
OPT-822/OPT-821 - Drug Profile 436
Tykerb - Drug Profile 437
SU011248 + Paclitaxel - Drug Profile 438
Imatinib + Vinorelbine - Drug Profile 440
Afinitor + Exemestane - Drug Profile 441
Everolimus + Trastuzumab + Vinorelbine - Drug Profile 442
Docetaxel + Doxorubicin + Cyclophosphamide - Drug Profile 444
Ixempra + Cyclophosphamide + Doxorubicin - Drug Profile 445
Vinflunine + Capecitabine - Drug Profile 447
Doxorubicine + Cyclophosphamide + Herceptin + Taxotere - Drug Profile 448
Afatinib + Vinorelbine - Drug Profile 450
Afatinib - Drug Profile 452
Tykerb + Paclitaxel - Drug Profile 454
BSI-201 + Gemcitabine + Carboplatin - Drug Profile 455
Lapatinib + Trastuzumab - Drug Profile 457
Paclitaxel + Trastuzumab + GW572016 - Drug Profile 459
Tykerb + Votrient - Drug Profile 461
Avastin + Xeloda - Drug Profile 463
Letrozole + Zoledronic Acid - Drug Profile 465
Avastin + Herceptin + Docetaxel - Drug Profile 467
Herceptin + Avastin - Drug Profile 469
Pertuzumab + Herceptin + Docetaxel - Drug Profile 470
Pertuzumab + Herceptin - Drug Profile 472
Avastin + Taxane - Drug Profile 474
Herceptin + Docetaxel + 5-fluorouracil + Epirubicin + Cyclophosphamide - Drug Profile 476
Zometa + Femara - Drug Profile 478
Myocet + Taxol + Herceptin - Drug Profile 480
Trastuzumab-DM1 + Pertuzumab - Drug Profile 481
Paclitaxel/Docetaxel + Lapatinib - Drug Profile 483
Lapatinib + Trastuzumab + Letrozole - Drug Profile 485
IMC-1121B + Docetaxel - Drug Profile 487
Lapatinib + Trastuzumab + Anastrozole - Drug Profile 489
Lapatinib + Trastuzumab + Exemestane - Drug Profile 491
Aromasin + Entinostat - Drug Profile 493
RAD001 + Trastuzumab + Paclitaxel - Drug Profile 494
Nexavar + Capecitabine - Drug Profile 496
CT-P06 - Drug Profile 497
Herceptin - Drug Profile 498
Herceptin - Drug Profile 500
Avastin + Standard Chemotherapy - Drug Profile 502
Breast Cancer Therapeutics – Drug Profile Updates 504
Breast Cancer Therapeutics – Discontinued Products 531
Breast Cancer Therapeutics - Dormant Products 548
Breast Cancer – Product Development Milestones 610
Featured News & Press Releases 610
Jan 11, 2012: Cancer Research UK Launches Outpatients Phase II Clinical Trial Of Breast And Ovarian Cancer Drug 610
Jan 03, 2012: Eisai Receives J-Code From Centers For Medicare And Medicaid Services For Halaven Injection 613
Appendix 618
Methodology 618
Coverage 618
Secondary Research 618
Primary Research 618
Expert Panel Validation 619
Contact Us 619
Disclaimer 619
[Inhaltsverzeichnis ausblenden]

List of Tables
Number of Products Under Development for Breast Cancer, H1 2012 26
Products under Development for Breast Cancer – Comparative Analysis, H1 2012 27
Number of Products under Development by Companies, H1 2012 29
Number of Products under Investigation by Universities/Institutes, H1 2012 46
Comparative Analysis by Late Stage Development, H1 2012 72
Comparative Analysis by Mid Clinical Stage Development, H1 2012 73
Comparative Analysis by Early Clinical Stage Development, H1 2012 74
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 75
Products under Development by Companies, H1 2012 76
Products under Investigation by Universities/Institutes, H1 2012 106
Bristol-Myers Squibb Company, H1 2012 199
Boehringer Ingelheim GmbH, H1 2012 200
F. Hoffmann-La Roche Ltd., H1 2012 201
Kyowa Hakko Kirin Co., Ltd., H1 2012 203
Celsion Corporation, H1 2012 204
Abbott Laboratories, H1 2012 205
Biogen Idec Inc., H1 2012 206
Amgen Inc., H1 2012 207
Sanofi-Aventis, H1 2012 208
Adherex Technologies Inc., H1 2012 209
AstraZeneca PLC, H1 2012 210
Eli Lilly and Company, H1 2012 211
Viralytics Ltd., H1 2012 212
GlaxoSmithKline plc, H1 2012 213
Seattle Genetics, Inc., H1 2012 214
Tekmira Pharmaceuticals Corp., H1 2012 215
Genentech, Inc., H1 2012 216
Nektar Therapeutics, H1 2012 217
Biotec Pharmacon ASA, H1 2012 218
Bavarian Nordic A/S, H1 2012 219
Daiichi Sankyo Company, Ltd, H1 2012 220
Merck & Co., Inc., H1 2012 221
A&G Pharmaceutical, Inc., H1 2012 222
Oxford BioMedica plc, H1 2012 223
Infinity Pharmaceuticals, Inc., H1 2012 224
Generex Biotechnology Corporation, H1 2012 225
Takeda Pharmaceutical Company Limited, H1 2012 226
Ipsen S.A., H1 2012 227
MediGene AG, H1 2012 228
Celltrion, Inc., H1 2012 229
Bio-Path Holdings, Inc., H1 2012 230
Epeius Biotechnologies Corporation, H1 2012 400
Immunovative Therapies, Ltd., H1 2012 401
Oncozyme Pharma Inc., H1 2012 402
BerGenBio AS, H1 2012 403
CytomX, LLC., H1 2012 404
Assessment by Monotherapy Products, H1 2012 405
Assessment by Combination Products, H1 2012 406
Assessment by Stage and Route of Administration, H1 2012 409
Assessment by Molecule Type, H1 2012 412
Breast Cancer Therapeutics – Drug Profile Updates 504
Breast Cancer Therapeutics – Discontinued Products 531
Breast Cancer Therapeutics – Dormant Products 548
List of Figures
Number of Products under Development for Breast Cancer, H1 2012 26
Products under Development for Breast Cancer – Comparative Analysis, H1 2012 27
Products under Development by Companies, H1 2012 28
Products under Investigation by Universities/Institutes, H1 2012 45
Late Stage Products, H1 2012 72
Mid Clinical Stage Products, H1 2012 73
Early Clinical Stage Products, H1 2012 74
Discovery and Pre-Clinical Stage Products, H1 2012 75
Assessment by Monotherapy Products, H1 2012 405
Assessment by Combination Products, H1 2012 406
Assessment by Route of Administration, H1 2012 407
Assessment by Stage and Route of Administration, H1 2012 408
Assessment by Molecule Type, H1 2012 410
Assessment by Stage and Molecule Type, H1 2012 411
[Tabellenverzeichnis ausblenden]